Patent ID: 7186832

Claim:
A compound of the formula I: wherein R 1 and R 2 are each independently H, alkyl, or cycloalkyl; R 3 and R 4 are each independently selected from the group consisting of H, halo, alkyl, aryl, heteroaryl, heteroalicylic, —OH, —OR 7 , —NR 7 R 8 , —(CH 2 ) n C(O)OR 7 , —SO 2 R 7 , —(CH 2 ) n C(O)NR 7 R 8 , —C(S)NR 7 R 8 , —C(O)R 7 , —NR 7 C(O)R 8 , —NHC(O)OR 8 , —NR 7 C(O)NR 9 R 8 , —SO 2 NR 7 R 8 , —OC(O)OR 7 , —OC(O)NR 7 R, CN and NO 2 , wherein said alkyl, aryl, heteroaryl and heteroalicyclic groups may be further substituted with one or more substitutents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, —OR 7 , —NR 7 R 8 , —NR 7 C(O)R 8 , aryl, —C(O)OR 7 , cycloalkyl, haloalkyl, haloalkoxy, —C(O)R 7 , —NR 7 C(O)OR 8 , —SO 2 R 7 , —NR 7 C(O)NR 9 R 8 , —C(O)NR 7 R 8 and —SO 2 NR 7 R 8 ; R 5 is aryl, or heteroaryl, wherein said aryl or heteroaryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkyl substituted by ═N—OR 7 , alkoxy, halogen, hydroxy or protected hydroxy, —OR 7 , —NR 7 R 8 , —NR 7 C(O)R 8 , aryl, —C(O)OR 7 , cycloalkyl, haloalkyl, haloalkoxy, —C(O)R 7 , —NR 7 C(O)OR 8 , —SO 2 R 7 , —NR 7 C(O)NR 9 R 8 , —C(O)NR 7 R 8 , —SO 2 NR 7 R 8 , and —NR 7 SO 2 R 9 ; R 6 is H; R 7 , R 8 and R 9 are independently H, alkyl, alkylamino, amino, aralkyl, aryloxy, halo, cycloalkyl, heterocycloalkyl or aryl, wherein said alkyl, heterocycloalkyl, and aryl may be further substituted with a substituent selected from the group consisting of alkyl; heterocycloalkyl; aryl; aryl substituted by a heteroalicyclic group; trifluoroalkyl; —OH; alkoxy; amino; —NO 2 and —CN; wherein an amino moiety of R 7 , R 8 , and R 9 is optionally substituted with one or two of alkyl, aralkyl, aryl, aryloxyalkyl, aralkyloxyalkyl, heteroalicycloalkyl, heteroaralkyl, heteroaralkyloxy, cycloalkyl, heteroalicycloxy, heteroalicycloalkyl, and heteroalicyclic; alternatively, NR 7 R 8 can form a 5–7 membered heteroalicyclic ring or a 5–6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms selected from N, O, and S, and the cyclic structure formed about NR 7 R 8 may be substituted with a substitutent selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicylic, heteroalicycloalkyl, aryl, heteroaryl and halo; and wherein n=0–3; or a pharmaceutically acceptable salt thereof.